NCR Online Journal

Genes2Me Becomes the Largest COVID-19 RT PCR Kit Manufacturer in India

 Breaking News
  • No posts were found

Genes2Me Becomes the Largest COVID-19 RT PCR Kit Manufacturer in India

July 14
01:16 2022
Genes2Me Becomes the Largest COVID-19 RT PCR Kit Manufacturer in India
Real-Time PCR-based assays for the detection of SARS-CoV-2 specific RNA.
Genes2Me has become one of the largest COVID-19 RT PCR Kit manufacturers in India with its launch of the RT- Direct Multiplex RTPCR kit for COVID-19. This kit, a first-of-its-kind “Made in India” product, is based on the Gold Standard RTPCR technology and covers 3 target genes that are unique to SARS-COV-2 along with IC, making it significantly more advanced than kits that only cover 1 or 2 target genes. The nation’s testing endeavor has been expanded by Genes2Me.

Genes2Me has become one of the largest COVID-19 RT PCR Kit manufacturers in India with its launch of the RT- Direct Multiplex RTPCR kit for COVID-19. This kit, a first-of-its-kind “Made in India” product, is based on the Gold Standard RTPCR technology and covers 3 target genes that are unique to SARS-COV-2 along with IC, making it significantly more advanced than kits that only cover 1 or 2 target genes.

The Genes2Me COVID-19 RT-PCR Kit is a real-time reverse transcription-polymerase chain reaction (RT-PCR) test designed to qualitatively detect SARS-CoV-2 nucleic acid in nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swabs.

Many hospitals, medical centres, and diagnostic laboratories use real-time PCR-based diagnostic kits. The nation’s quest for affordable and trustworthy testing is intended to stop the COVID-19 pandemic from spreading.

Genes2Me has expanded the nation’s testing endeavour, one of the industries thought leaders in advanced molecular diagnostics and genetic testing, with the introduction of Real-Time PCR-based assays for detecting SARS-CoV-2 specific RNA.

During the acute phase of illness, the SARS-CoV-2 RNA is typically detected in respiratory specimens. Positive results indicate that SARS-CoV-2 RNA is present; however, the clinical connection with patient history and other diagnostic data is required to evaluate the patient’s infection status. Positive outcomes do not rule out bacterial illness or viral co-infection. The identified substance may not be the actual cause of the disease.

Negative results do not rule out SARS-CoV-2 infection and shouldn’t be the only factor considered when making patient management decisions. The clinical observations, patient history, and epidemiological data must be integrated with negative results.

When diagnosing suspected and asymptomatic patients for coronavirus, real-time PCR-based products are frequently employed. The time it takes for various PCR assays to provide accurate and trustworthy findings varies.

Genes2Me founder and CEO Mr Neeraj Gupta says,” The COVID-19 VIRALDTECT Multiplex Real-Time PCR Kit from Genes2Me is extremely sensitive, specific, and capable of producing repeatable results. There are both negative and positive controls in the package. The kit also features an internal control, ORF1ab gene, E gene, and N gene coverage in a single tube multiplexed design. Additionally, four distinct dyes are used to mark the probes to enable multiplexing in a single tube”.

He further says, “The kit demonstrates its ability to work with Real-time PCR-based systems that have four-plex with FAM, ROX, HEX/VIC, and Cy5 Channels. After experimenting in accordance with the necessary circumstances and protocols, findings, whether positive or negative, can be acquired within two hours. Nasal samples and oropharyngeal swabs are the best samples to use in the detection process.”.

Genes2Me has been developing a range of cutting-edge strategies to tackle the threat posed by COVID-19 ever since the epidemic began. Genes2Me began producing the best molecular IVD kits for COVID-19 testing that are ICMR validated, and CE-IVD certified. It has provided more than 50 million tests and is now recognised as one of the top producers of IVD kits for COVID-19 testing.

Genes2Me, a genomics-focused diagnostic firm founded in 2016 by Neeraj Gupta and Ritu Gupta, aims to consistently produce distinctive and innovative IVD genetic solutions to improve global health, even in resource-limited locations. Genes2Me has been helping clinicians and individuals in India to understand complex genetic disorders and vulnerability to various health disorders through its wide variety of genetic tests. As a producer of IVD kits and a provider of genetic testing services in the markets of Personalized Health, Mother and Child Care, Oncology & Infectious Diseases, the company has been successful in delivering Innovative Genetic Testing solutions.

Media Contact
Company Name: Genes2Me Private Limited
Contact Person: Mukesh Kumar
Email: Send Email
Phone: 1001214030
Address:1105, SAS Tower Medicity, Sector-38
City: Gurugram
State: Haryana
Country: India
Website: https://www.genes2me.com

Related Articles